logo-loader
HealthPharma & Biotech
viewGlaxoSmithKline PLC

GSK chairman steps down after consumer healthcare merger with Pfizer

GSK chairman Sir Philip Hampton said following a deal with Pfizer to merge their consumer businesses, he believes "this is the right moment" to step down

GSK
GSK and Pfizer expect their deal to deliver cost savings and synergies

GlaxoSmithKline PLC (LON:GSK) chairman Sir Philip Hampton is to hang up his hat after more than three years in the top job.

The pharmaceuticals giant, which agreed in December to merge its consumer healthcare business with Pfizer Inc’s (NYSE:PFE) rival operation, said it has started the process to find a successor to Hampton.

READ: GlaxoSmithKline spikes higher as it inks US$12.7bn consumer healthcare deal with Pfizer

Hampton became chairman of GSK in May 2015, a month after being appointed as deputy chairman and four months after joining the board.

“Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new chair to oversee this process through to its conclusion over the next few years and to lead the Board into this next phase for GSK,” he said.

GSK will own 68% of the combined consumer healthcare business, which brings together products such as Panadol and Advil with combined sales of US$12.7bn.

The deal is expected to deliver cost savings and synergies of about US$650mln per year.

Further down the line, the companies plan to separately list the enlarged business, which will be named GSK Consumer Healthcare.

Glaxo shares were down 0.4% to 1,493p on Monday afternoon.

-- Adds share price --

Quick facts: GlaxoSmithKline PLC

Price: 1651.8 GBX

LSE:GSK
Market: LSE
Market Cap: £82.4 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IGas is a 'diverse business with lots of opportunities' says CEO Bowler

Onshore UK focused IGas’s (LON:IGAS) production currently is 850,000 barrels per year, but that is dwarfed by its shale acreage in the East Midlands. This compares favourably with major shale plays in the US, says Bowler, who believes the reserves are sufficient to provide all the UK’s gas...

10 hours, 15 minutes ago

RNS

Director/PDMR Shareholding

2 days, 8 hours ago

Director/PDMR Shareholding

2 days, 8 hours ago

Director/PDMR Shareholding

2 days, 8 hours ago

Director/PDMR Shareholding

2 days, 8 hours ago

Director/PDMR Shareholding

6 days, 7 hours ago

Director/PDMR Shareholding

6 days, 9 hours ago

Director/PDMR Shareholding

1 week, 1 day ago

Director/PDMR Shareholding

2 weeks, 3 days ago

2 min read